This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

RNA Leaders Europe
Save the dates 5-6 March 2025
Congress Center BaselBasel, Switzerland

Paul Nioi
VP, Discovery & Translational Research at Alnylam Pharmaceuticals


Paul joined Alnylam in March 2018 and is responsible for leading the Discovery and Translational Research function. He has overall responsibility for new target identification/validation, biomarkers and all preclinical drug discovery programs. Building on his depth of prior experience, he also leads the Alnylam Human Genetics center which focuses on identification of new drug targets from large genotype-phenotype datasets.

Paul has over 18 years of biotech and pharma experience. He joined Alnylam following a tenure at Amgen and deCODE genetics where he held roles of increasing responsibility. Most recently he was Director of the Translational Systems Biology group and led a large team that was focused on making discoveries from human genetics to influence target selection.

Paul obtained his academic training at the University of Edinburgh (BSc, Pharmacology) and the University of Dundee (PhD, Molecular Biology).

Agenda Sessions

  • Keynote Panel: RNA Partnerships of Big Pharma, Biotech, Industry Providers – What Does Success Look Like?

  • ALN-APP, the first investigational RNAi therapeutic in development for Alzheimer’s disease